Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells

Cell Death and Differentiation

Volumn 13, Issue 2, 2006, Pages 202-211

  Monteleone, Gi ^a   Franchi, L ^a   Fina, D ^a   Caruso, R ^a   Vavassori, P ^a   Monteleone, I ^a   Calabrese, E ^a   Naccari, G C ^b   Bellinvia, S ^b   Testi, R ^a   Pallone, F ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b GIULIANI S P A   (Italy)

Author keywords

Colon cancer; EGFR; Mesalazine; SH PTP2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MESALAZINE; PHOSPHATASE; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADENOCARCINOMA; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MESALAMINE; PHOSPHORYLATION; PROTEIN-TYROSINE-PHOSPHATASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; SHP1 PROTEIN TYROSINE PHOSPHATASE;

EID: 30844460628     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401733     Document Type: Article

References (34)

1. Keighley MRB (2003) Gastrointestinal cancers in Europe. Aliment. Pharmacol. Ther. 18 (Suppl. 3): 7-30
2. Beauchamp RD, Peeler MO and DuBois RN (1996) Recent advances in the management of colorectal polyps. Curr. Opin. Gastroenterol. 12: 12-17
3. Huls G, Koomstra JJ and Kleibeuker JH (2003) Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 362: 230-232
4. Smalley WE and DuBois RN (1997) Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol. 39: 1-20
5. Koehne CH and Dubois RN (2004) COX-2 inhibition and colorectal cancer. Semin. Oncol. 31 (Suppl 7): 12-21
6. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM and Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA 284: 1247-1255
7. Mukherjee D, Nissen SE and Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954-959
8. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA and Egger M (2004) Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 364: 2021-2029
9. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW and Burgess AW (2003) Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp. Cell Res. 284: 31-53
10. Bradley SJ, Garfinkle G, Walker E, Salem R, Chen LB and Steele Jr G (1986) Increased expression of the epidermal growth factor receptor on human colon carcinoma cells. Arch. Surg. 121: 1242-1247
11. Janmaat ML and Giaccone G (2003) The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today 39 (Suppl C): 61-80
12. Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ and Threadgill DW (2002) Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc. Natl. Acad. Sci. 99: 1521-1526
13. Mendelsohn J (2001) The epidermal growth factor receptor as a target for cancer therapy. Endocrine -Relat. Cancer 8: 3-9
14. Mendelsohn J and Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565
15. Eaden J, Abrams K, Ekbom A, Jackson E and Mayberry J (2000) Colorectal cancer prevention in ulcerative colitis: A case-control study. Aliment. Pharmacol. Ther. 14: 145-153
16. Eaden J (2003) Review article: The data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 182: 15-21
17. Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I and Schmiegel W (2003) Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 24: 443-451
18. Narisawa T and Fukaura Y (2003) Prevention by intrarectal 5-aminosalicylic acid of N-methylnitrosourea-induced colon cancer in F344 rats. Dis. Colon Rectum 46: 900-903
19. Brown WA, Farmer KC, Skinner SA, Malcontenti-Wilson C, Misajon A and O'Brien PE (2000) 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig. Dis. Sci. 45: 1578-1584
20. MacGregor DJ, Kim YS, Sleisenger MH and Johnson LK (2000) Chemoprevention of colon cancer carcinogensis by balsalazide: Inhibition of azoxymethane-induced aberrant crypt formation in the rat colon and intestinal tumor formation in the B6-Min/+ mouse. Int. J. Oncol. 17: 173-179
21. Frieri G, Pimpo MT, Palumbo GC, Onori L, Viscido A, Latella G, Galletti B, Pantaleoni GC and Caprilli R (1999) Rectal and colonic mesalazine concentration in ulcerative colitis: Oral vs oral plus topical treatment. Aliment. Pharmacol. Ther. 13: 1413-1417
22. Frieri G, Giacomelli R, Pimpo M, Palumbo G, Passacantando A, Pantaleoni G and Caprilli R (2000) Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 47: 410-414
23. Moghal N and Sternberg PW (11999) Multiple positive and negative regulators of signaling by the EGF-receptor. Curr. Opin. Cell Biol. 11: 190-196
24. Zhang ZY (1998) Protein-tyrosine phosphatases: Biological function, structural characteristics, and mechanism of catalysis. Crit. Rev. Biochem. Mol. Biol. 33: 1-52
25. Noguchi T, Matozaki T, Horita K, Fujioka Y and Kasuga M (1994) Role of SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in insulin-stimulated Ras activation. Mol. Cell. Biol. 14: 6674-6682
26. Tonks NK and Neel BG (2001) Combinatorial control of the specificity of protein tyrosine phosphatases. Curr. Opin. Cell Biol. 13: 182-195
27. Noguchi T, Matozaki T, Fujioka Y, Yamao T, Tsuda M, Takada T and Kasuga M (1996) Characterization of a 115-kDa protein that binds to SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in Chinese hamster ovary cells. J. Biol. Chem. 271: 27652-27658
28. Cossette LJ, Hoglinger O, Mou L and Shen SH (1996) Localization and down-regulating role of the protein tyrosine phosphatase PTP2C in membrane ruffles of PDGF-stimulated cells. Exp. Cell Res. 223: 459-466
29. Marengere LE, Waterhouse P, Duncan GS, Mittrucker HW, Feng GS and Mak TW (1996) Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 272: 1170-1173
30. Reeves SA, Sinha B, Baur I, Reinhold D and Harsh G (1995) An alternative role for the src-homology-domain-containing phosphotyrosine phosphatase (SH-PTP2) in regulating epidermal-growth-factor-dependent cell growth. Eur. J. Biochem. 233: 55-61
31. Cunnick JM, Dorsey JF, Munoz-Antonia T, Mei L and Wu J (2000) Requirement of SHP2 binding to Grb2-associated binder-1 for mitogen-activated protein kinase activation in response to lysophosphatidic acid and epidermal growth factor. J. Biol. Chem. 275: 13842-13848
32. Schaeper U, Gehring NH, Fuchs KP, Sachs M, Kempkes B and Birchmeier W (2000) Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J. Cell Biol. 149: 1419-1432
33. Neel BG, Gu H and Pao L (2003) The 'Shp'ing news: Sh2 domain-containing tyrosine phosphatses in cell signalling. Trends Biochem. Sci. 28: 284-293
34. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW and MacDonald TT (2001) Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J. Clin. Invest. 108: 601-609